Discoidin Domain Receptor Tyrosine Kinase 1 (DDR1): A Novel Predictor for Recurrence of Hepatocellular Carcinoma After Curative Resection

24 November 2021: Clinical Research

Meng Xu ^CDEFG , Chenghao Cui ^AB*

DOI: 10.12659/MSM.933109

Med Sci Monit 2021; 27:e933109

Table 2 Correlation between DDR1 and clinicopathologic characteristics.

Clinical Characteristic	Patients Number	DDR1 in serum		P	DDR1 in tumor		P
Clinical Characteristic	Patients Number	Low	High	P	Low	High	P
Age
≤50	54	21	33	0.713	19	35	1.000
>50	66	28	38	0.713	23	43	1.000
Sex
Male	31	10	21	0.295	10	21	0.808
Female	89	39	50	0.295	32	57	0.808
AFP
≤400 ng/mL	93	37	56	0.664	31	62	0.499
>400 ng/mL	27	12	15	0.664	11	16	0.499
ALT
≤75 U/L	79	34	45	0.700	26	52	0.689
>75 U/L	42	16	26	0.700	16	26	0.689
Tumor size
≤5 cm	67	30	37	0.354	23	44	1.000
>5 cm	53	19	34	0.354	18	34	1.000
Tumor number
Single	103	41	62	0.603	37	66	0.785
Multiple	17	8	9	0.603	5	12	0.785
HbsAg
Negative	18	6	12	0.606	8	10	0.425
Positive	102	43	59	0.606	34	68	0.425
Liver cirrhosis
No	22	10	12	0.639	10	12	0.323
Yes	98	39	59	0.639	32	66	0.323
Microvascular invasion
No	46	25	21		23	23
Yes	74	24	50		19	55
CTC
≤2/5 ml	61	31	30		30	31
>2/5 ml	59	18	41		12	47
Encapsulation
Complete	81	32	49	0.696	24	57	0.102
Incomplete	39	17	22	0.696	18	21	0.102
Satellite lesion
No	104	40	64	0.274	34	70	0.259
Yes	16	8	8	0.274	8	8	0.259
Child-Pugh score
A	111	46	65	0.736	34	74	0.274
B	9	3	6	0.736	5	4	0.274
Edmondson stage
I–II	73	31	42	0.664	23	50	0.334
III–IV	47	18	29	0.664	19	28	0.334
BCLC Stage
0-A	94	36	58	0.368	33	61	1.000
B-D	26	13	13	0.368	9	17	1.000